Amendments

In the Specification:

On page 37, please substitute the following Table 4 for the pending Table 4:

	Plasmid	Antiviral activity (U/ml)
Q'	LAP-mIFNβ	0
	$PorcLAP$ - $mIFN\beta$	256
	mIFNβ-LAP	256
and the second		

Please insert the Sequence Listing at the end of the application.

In the Claims:

Ľ

BI

Please substitute the following claim 3 for the pending claim 3:

3. (Once amended) The use as claimed in claim 1 wherein the proteolytic cleavage site is a matrix metalloproteinase (MMP) cleavage site.

Please substitute the following claim 4 for the pending claim 4;

4. (Once amended) The use as claimed in claim 1 wherein the pharmaceutically active is a growth factor, differentiation factor, cytokine, chemokine, trophic factor, cytokine inhibitor, cytokine receptor, free-radical scavenging enzyme, peptide mimetic, protease inhibitor, tissue inhibitor of metalloproteinase sub class, inhibitor of serine protease, chemotherapeutic agent or peptide nucleic acid sequence.